Prostate Cancer Update: 2007

    August 2008 in “ Current Opinion in Internal Medicine ”
    Amy Lin, Eric J. Small
    New to Finasteride? There is a guide in the encyclopedia. Read the guide →
    Image
    Studysummary This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    In 2007, prostate cancer research made strides in risk assessment, diagnosis, and treatment. Key findings included the prognostic value of the tertiary Gleason 5 pattern and PSA levels post-finasteride treatment, the benefits of active treatment in elderly men, and the development of a comprehensive nomogram for salvage radiotherapy. Studies highlighted the cardiovascular risks associated with androgen deprivation therapy (ADT), with one study of 4892 patients showing increased cardiovascular death associated with ADT, and another indicating ADT could hasten fatal myocardial infarction in men over 65. A multinational trial of 809 men found that atrasentan did not improve outcomes in hormone-refractory prostate cancer (HRPC), and a phase II study of 82 patients provided baseline data for taxane-resistant HRPC. The research underscored the need for personalized treatments and further investigation into ADT's cardiovascular effects and treatments for HRPC.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results